Assessment of vaccination tolerance to the first component of Gam-COVID-Vac according to one site

Abstract

Aim. To assess the tolerability of vaccination with the first component of Gam-COVID-Vac (Sputnik V), the frequency and nature of adverse events following immunization (AEFI) depending on gender, age, obesity, and chronic diseases.Material and Methods. The study included male and female patients who received the first component of the Gam-COVIDVac vaccine at MSU Medical Center. Subsequently, after 14 days, a remote survey of respondents was conducted to collect the data regarding the development of adverse events requiring the use of drug treatment or medical care.Results. The study included 732 participants. Two-thirds of the respondents (65.8%) reported the development of AEFI: pain at the injection site (46.9%), fever (25.5%), muscle pain (29.9%), and headache (27%). At the same time, women noted the occurrence of AEFI more often than men (72.4% vs 57.5%, p < 0.05), and AEFI duration was also longer. Patients over 60 years of age reported less fever than patients under 40 years of age (21.0% vs 31.1%; p < 0.031). Young age and female gender were independent predictors of AEFI after vaccination with the first component of the Sputnik V vaccine. Obesity and a history of reported chronic non-infectious diseases did not correlate with the occurrence of AEFI.Conclusion. Adverse events after the administration of the first component of Gam-COVID-Vac (Sputnik V) were of short duration and were easily tolerated by both young and old patients.